Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 24, 1524-1533, October 1, 1964]
© 1964 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Condit, P. T.
Right arrow Articles by Boles, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Condit, P. T.
Right arrow Articles by Boles, G. W.

Methotrexate and Radiation in the Treatment of Patients with Cancer*

P. T. Condit, G. R. Ridings{dagger}, J. W. Coin{ddagger}, G. R. Williams, D. Mitchell, Jr.§ and G. W. Boles

( Oklahoma Medical Research Institute; Departments of Medicine, Radiology and Surgery, University of Oklahoma School of Medicine; and Department of Radiology, St. Anthony Hospital, Oklahoma City, Oklahoma)

About one-third of patients with squamous carcinoma of the head and neck treated with methotrexate experience partial regression of tumors with associated symptomatic relief for a period of 1–3 months. Complete regression for longer periods can occur but is unusual. About two-thirds derive temporary symptomatic relief, particularly reduction of pain. These results can be achieved by large, infrequent intravenous doses with little or no drug toxicity. Intra-arterial administration of methotrexate confers no obvious advantage.

Methotrexate added to conventional protracted schedules of radiation therapy results in unacceptable drug toxicity but can be combined with short intensive courses of radiation without appreciable toxicity. The occurrence of prolonged remissions in patients with squamous carcinoma of the head and neck after treatment with less than curative doses of radiation plus methotrexate suggests that the drug potentiates the therapeutic effects of radiation.

* Supported by Grants No. T-118 and T-119 and by a Florence L. Fenton Memorial Grant for Cancer Research from the American Cancer Society, and by Grant No. CA-05815 from the National Institutes of Health.

Presented at the 54th Annual Meeting of the American Association for Cancer Research, Toronto, Canada, May 24, 1963.

{dagger} Present address: Department of Radiology, School of Medicine, University of Missouri, Columbia, Missouri.

{ddagger} Present address: Providence Hospital, Anchorage, Alaska.

§ Present address: Billings Deaconess Hospital, Billings, Montana.

Received 3/ 2/64.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1964 by the American Association for Cancer Research.